Hello! I'm your financial analysis assistant. This article from "Shenlan Guan" serves as a wake-up call for those who are still blindly optimistic about the pharmaceutical outsourcing industry.
In simple terms, the pharmaceutical research and development outsourcing (CRO/SMO) industry is experiencing severe pain after a period of extreme fluctuations. Previously, it was the pharmaceutical companies that were eager to work with CROs; now, it's the CROs that are seeking payment from the pharmaceutical companies. With less money available, companies have resorted to price wars, which has led to a decline in service quality, unpaid salaries, a surge in lawsuits, and even threats to the data integrity of new drug developments and the safety of patients.
Below, I will break down this news into five key aspects to help you fully understand the crisis in the industry:
---
1. Where did the money go? The upstream is bleeding, and the downstream is running out of resources
Core logic: Pharmaceutical companies are running out of money, leaving CROs with no options but to struggle.
Over the past few years (2015-2021), innovative drugs were in high demand, and capital flooded into the industry. Pharmaceutical companies (Biotechs) had plenty of funds and were willing to pay high prices to hire CROs (contract research organizations) and SMOs (site management organizations) to conduct experiments. Back then, CROs were in a position of strength.
But now the tide has turned:
- Pharmaceutical companies are short of cash: Many startups are having difficulty raising funds, or their first drugs are not selling well (due to price cuts from government procurement or fierce competition), resulting in cash flow problems.
- Payment delays: Pharmaceutical companies are unable to pay CROs, which in turn cannot pay SMOs, and SMOs cannot pay their frontline staff (CRCs/CRAs).
- Evidence of the crisis: Yuan Biology's annual report shows a significant increase in accounts receivable (money owed to them), especially for debts from 1-2 years ago. Even established companies like BeiDa Pharmaceutical have seen a 50% cut in research and development spending, let alone smaller firms.
Popular analogy: It's like a situation where everyone was competing to renovate houses, and the renovation companies (CROs) and contractors (SMOs) were making huge profits. Now that houses are hard to sell and homeowners (pharmaceutical companies) can't pay, the renovation companies have to take on low-price projects and can't even pay their workers, causing the entire chain to suffer financial losses.
---
2. Why are there so many lawsuits? "Double-standard contracts" and blame-shifting
Core logic: Low-price bidding has led to vague contract terms, resulting in legal disputes.
In the past, companies had money and signed contracts with clear standards. Now, to win bids, CROs offer prices far below their costs.
- Prices below cost: Both parties know the CROs will lose money, but they sign the contracts anyway; the CROs know they can't meet the standards, but they accept the contracts. This is what's known as a "double-standard contract"—promising high standards during bidding but failing to meet them in execution.
- Blame game: When projects are delayed or data errors occur, pharmaceutical companies accuse CROs of breaching contracts or failing to meet quality standards, while CROs blame pharmaceutical companies for unreasonable protocols, poor hospital cooperation, or slow payments.
- Lawsuit surge: Since contracts are ambiguous about who is responsible, both parties resort to litigation to force payment or get exemptions. For example, Medicsyn was sued for 159 million yuan, and Nosteg was involved in a case worth 179.9 million yuan—these are just the tip of the iceberg.
Popular analogy: It's like you pay 50 yuan for a full Chinese meal. The chef (CRO) accepts the order, but the money isn't even enough for the ingredients. When the food is delivered and tastes bad, you say the chef is bad, and the chef says the ingredients are of poor quality or the deadline was too tight. In the end, it's hard for a judge to determine who is at fault because the deal was inherently unfair from the start.
---
3. Frontline employees are becoming the victims: Salary cuts, unpaid wages, and high turnover
Core logic: With profits squeezed to the minimum, the first to suffer are the dignity and quality of work.
CROs and SMOs are labor-intensive industries. When profits are eroded by price wars, companies cut staff costs.
- Overloading employees: A CRA used to manage 3-4 hospitals; now they might manage more than 10. A CRC has to oversee dozens of patients, working tirelessly.
- Unpaid wages: It's common for SMOs to owe or cut employees' salaries. To survive, employees either quit or take on side jobs.
- Vicious cycle: When employees leave, new hires need training, which reduces efficiency and leads to more errors. New hires, under pressure and with low salaries, also tend to leave, creating a cycle of low wages, poor quality, high turnover, and even lower efficiency.
Popular analogy: It's like a factory speeding up the production line to save money but not increasing workers' wages, forcing them to do three people's work. As a result, workers are overworked, errors increase, and the quality of the products (clinical trial data) suffers, leading to financial losses for the factory.
---
4. The biggest threat: The risk of data fraud, endangering patient safety
Core logic: To meet deadlines and earn money, companies are compromising on data integrity, which poses a serious threat to patient safety.
The core of clinical trials is the authenticity of data. Fake data can lead to dangerous new drugs on the market.
- Formalities over substance: To meet deadlines set by pharmaceutical companies (e.g., a certain number of patients must be enrolled by a certain date or else no payment), lower-level staff may deceive patients or manipulate data for convenience.
- Ineffective supervision: Overburdened CRAs may conduct superficial inspections and fail to detect errors.
- Serious consequences: If regulatory agencies (like the NMPA or FDA) discover data fraud, new drug applications will be rejected, costing companies millions. Even worse, if fake data makes it to market, it can endanger patients' lives.
Popular analogy: It's like construction workers cutting corners during a project, using substandard materials or improper reinforcement. Although the building is completed on time, it could collapse at any moment, posing a real danger to the occupants. In the pharmaceutical industry, this "building" represents patients' lives.
---
5. How to break the cycle? Technology and standards are the solutions
Core logic: The industry must move away from relying on mass labor and price cuts and embrace technology and standardization to improve efficiency.
- Standardization: Companies like Shengen Medicine and TaiMei Medical are standardizing every step of CRC operations (how to record, submit, and when to complete them) and automating them with software to reduce human errors and increase efficiency.
- AI adoption: By 2026, AI will no longer be a concept but a essential tool. Internationally, ICON is collaborating with Anthropic to use AI models in clinical trials. Domestically, eSource (electronic source data) and decentralized trials are being promoted. Wearable devices are used to monitor patients remotely, and AI is used to verify data automatically.
- Value of technology: Technology isn't about replacing people but about ensuring data quality and delivery speed without increasing labor costs. This is the key to CRO/SMO survival in the future.
Popular analogy: In the past, the strategy was to use more people; more workers meant more power but also more chaos. Now, we use AI as a "super inspector" and standardized processes as "automatic navigation." With fewer people, everyone works efficiently and accurately, saving money and maintaining quality.
---
Summary
This article highlights a harsh reality: the pharmaceutical outsourcing industry is transitioning from rapid growth to a more refined and competitive landscape.
- Short-term: Difficulties such as unpaid wages, lawsuits, and layoffs are inevitable as pharmaceutical companies' cash flows have not fully recovered.
- Long-term: Only companies that use technology and digital tools to improve efficiency and adhere to data compliance will survive. Those that rely on low-price bidding and exploit frontline employees will be eliminated by the market.
For individuals in this industry, improving digital skills and understanding compliance standards is more important than just working hard. For investors in the pharmaceutical sector, be wary of companies with high accounts receivable, frequent lawsuits, and reliance on low-price competition, as these are signs of potential risks.